Re for Personalized NanoMedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland,

Re for Personalized NanoMedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, Queensland, Australia. 2School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia. 3Faculty of Biotechnology, Vietnam National University of Agriculture, Hanoi, Vietnam. Received: 12 May 2015 Accepted: 25 JuneTo enable an electrochemical readout, 50 L of 0.5 M H2SO4 was used to stop the HRP/TMB reaction after 15 mins and to convert TMB to its electrochemically active form [21]. Fifty microlitres of the resulting TMB solution was added onto screen-printed electrodes (CH Instruments, USA) and electrochemical response was detectedReferences 1. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31(2):89?7. 2. Friso S, Udali S, Guarini P, Pellegrini C, Pattini P, Moruzzi S, et al. Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk. Cancer Epidemiol Biomarkers Prev. 2013;22(3):348?5. doi:10.1158/1055-9965.EPI-12-0859. 3. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239?9. doi:10.2217/epi.09.33. 4. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85?3. 5. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27362935 2006;5(1):37?0. doi:10.1038/nrd1930. 6. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457?3. doi:10.1038/nature02625. 7. Wee EJ, Peters K, Nair SS, Hulf T, Stein S, Wagner S, et al. DS5565 site Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene. 2012;31(38):4182?5. doi:10.1038/onc.2011.584. 8. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992;89(5):1827?1. 9. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994;22(15):2990?.Wee et al. Clinical Epigenetics (2015) 7:Page 9 of10. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res. 2007;67(18):8511?. 11. Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat Protoc. 2011;6(4):468?1. 12. Hirst M, Marra MA. Next generation sequencing based approaches to epigenomics. Brief Funct Genomics. 2010;9(5?):455?5. 13. Zerilli F, Bonanno C, Shehi E, Amicarelli G, Adlerstein D, Makrigiorgos GM. Methylation-specific loop-mediated isothermal amplification for detecting hypermethylated DNA in simplex and multiplex formats. Clin Chem. 2010;56(8):1287?6. 14. Nair SS, Coolen MW, Stirzaker C, Song JZ, Statham AL, Strbenac D, et al. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA methylation analysis reveal CpG sequence coverage bias. Epigenetics Off J DNA Methylation Soc.